Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association Cigarette smoking has been found to harm nearly every organ and organ system in the body and diminishes a person's overall health. Although a survey by Japan's Ministry of Health, Labor and Welfare showed a declining trend in smoking in Japan, with the percentage of smokers falling to 21.6% in 2013 from 30.5% in 2001, the percentage of male smokers was still high, at 33.7% in 2013. Cigarette smoking has been associated with the carcinogenesis of several human cancers including urological neoplasms (3,4). Several clinical prognostic factors of advanced RCC have been reported to predict oncological outcomes (5,6). However, associations between cigarette smoking, which are related to the well-known lifestyle risk factors for RCC (7), and survival in patients with advanced RCC have not been well studied.
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Introduction
Renal cell carcinoma (RCC) accounts for~90% of all kidney malignancies. The Japanese incidence of kidney and other urinary neoplasms was estimated to increase to 19 550 in 2009 by Japanese projected cancer statistics (1) . The Japanese Urological Association (JUA) collected data on clinical and pathological characteristics and outcomes of RCC among patients diagnosed in 2007 (2) . This database contains data of the clinicopathological status and clinical trend before the molecular-targeted therapy era of more than 3600 Japanese patients with RCC. In this database, oncological outcomes depend on the clinical stage and histological subtype was reported as a primary analysis (2) , and despite the widespread use of imaging, 26.4% of patients were still newly diagnosed with RCC presenting with an advanced disease above Stage 3. Cigarette smoking has been found to harm nearly every organ and organ system in the body and diminishes a person's overall health. Although a survey by Japan's Ministry of Health, Labor and Welfare showed a declining trend in smoking in Japan, with the percentage of smokers falling to 21.6% in 2013 from 30.5% in 2001, the percentage of male smokers was still high, at 33.7% in 2013. Cigarette smoking has been associated with the carcinogenesis of several human cancers including urological neoplasms (3, 4) . Several clinical prognostic factors of advanced RCC have been reported to predict oncological outcomes (5, 6) . However, associations between cigarette smoking, which are related to the well-known lifestyle risk factors for RCC (7) , and survival in patients with advanced RCC have not been well studied.
Smoking status has been reported to be associated with worse outcomes in other urological malignant neoplasms of prostate and urothelial organs (8) (9) (10) . It is hypothesized that long-term, highdose exposure to cigarette smoke results in more aggressive cancer phenotypes or adverse internal body environment changes, negatively affecting prognosis through rapidly progressive characteristics or poor treatment effects. It remains necessary for Japanese urological investigators to pool Japanese patient data when trying to draw meaningful conclusions. In the current study, we examined the impact of cigarette smoking status on the survival of patients with advanced RCC using this multi-institutional Japanese national database.
Patients and methods

Ethical considerations
The study has been approved by a suitably constituted Ethics Committee of each institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki
Study design
We performed a retrospective cohort study using data from a multiinstitutional national database of the JUA. This RCC registry program included clinicopathological details, such as age, gender, height, weight, body mass index (BMI), family history, past history of hypertension and diabetes, cigarette smoking status, reason for diagnosis, fever symptoms over 38°C, Eastern Cooperative Oncology Group (ECOG) performance status (PS), serum laboratory data including albumin (Alb), alkaline phosphatase (ALP), Creactive protein (CRP), creatinine (Crea), hemoglobin (Hb), lactic dehydrogenase (LDH), and total calcium (Ca) at diagnosis, clinical TNM classification and stage, histopathology, initial and secondary treatment and clinical outcomes.
Patients
We analyzed data from the computer-based JUA registry of patients with RCC diagnosed in 2007 (2) . Fifteen patients diagnosed with oncocytoma were excluded from the analysis. From 340 Japanese institutions, 3648 patients were registered. We selected patients with Stage 3 or higher for analysis because such patients have a high risk for concomitant metastatic cancer cells after nephrectomy. The study ultimately comprised 963 patients who were clinically diagnosed at Stage 3 (406 patients) or 4 (557 patients). Standardization of the indications of medical treatment, nephrectomy, cytoreductive surgery and metastasectomy were impossible because of the multiple centers and retrospective design. Follow-up surveys were conducted according to the protocol of each facility.
Clinical characteristics
Clinical and pathological information was evaluated with reference to the fourth edition of The General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma, edited by the JUA and The Japanese Society of Pathology and based on Union International Contre le Cancer 2009. Albumin-corrected Ca was calculated as: total Ca −0.707 × (Alb −3.4), (5) and the corrected Ca value was used for survival analyses. ALP, CRP, Crea and Hb values were classified as non-high and high and defined with each facility's reference value. The abnormality of LDH and corrected Ca were defined as over 1.5-times each facility's reference value and 10 mg/dl or more, respectively. Cigarette smoking status at the time of diagnosis was classified as non-smoker, ex-smoker, light smoker (19 cigarettes or fewer per day) and heavy smoker (20 cigarettes or more per day) (11) . We determined that the threshold of 20 (one box) was appropriate from its accuracy of patient reporting, BMI was stratified into three grades, being, underweight, normal and overweight, with cut-offs of 18.5 and 25 (12) .
Statistical analysis
We examined the relationship between cigarette smoking status at diagnosis and prognosis. There are some confounding factors for the prognosis of cigarette smoking status. In RCC registry program data, confounding variables for cigarette smoking status are age, gender, BMI, medical history, symptoms, ECOG PS, serum laboratory blood data, and clinical stage (Table 1) . For statistical analysis, Fisher's exact test was used to evaluate incidences. The Kaplan-Meier method was used to calculate overall survival (OS) and cancer-specific survival (CSS). The log-rank test with one-way analysis of variance was used in univariate analyses. To investigate whether cigarette smoking status at diagnosis was an independent factor, cigarette smoking status at diagnosis and confounding variables were analyzed in multivariate analysis. Multivariate Cox regression models with stepwise selection were used to examine OS and CSS. In Cox regression models, proportional hazards assumptions were systematically verified using the martingale residualbased test. A P value of 0.05 was determined as statistically significant. Hazard ratios with 95% confidence intervals are shown. All statistical analyses were performed using the statistical software EZR (13) , which is based on the open-source R statistical software ver. 3.0.2.
Results
Patient characteristics and treatment
The median follow-up period for 963 patients clinically diagnosed with RCC at Stage 3 or 4 was 842 days (the lower quartile was 194 days and the upper quartile was 1981 days). Median and range for age were 66 and 18-93 years, respectively. Table 1 summarizes the clinical characteristics of the patients analyzed. Of 963 patients, 720 (74.8%) were nephrectomized (388 (95.6%) of 406 at Stage 3 and 332 (59.6%) of 557 at Stage 4, respectively). A total of 440 patients had no cigarette smoking history at the time of diagnosis, and 116 patients had a past history of cigarette smoking. In 147 currently active smokers, 87 patients were heavy smokers of 20 cigarettes or more per day. For the association between smoking status and stage distribution, former cigarette smoking history (P = 0.25) and current status at diagnosis (P = 0.64) were not found to be statistically correlated with clinical stages using Fisher's exact tests. Table 2 summarizes the clinical characteristics in 703 patients with renal cell carcinoma at smoking status without missing data.
Prognostic variables of cigarette smoking status for OS and CSS
During the study follow-up, 392 (40.7%) and 351 (36.4%) patients died from all causes and RCC, respectively. Risks for total death were 21.9%, 38.8% and 46.5% at 1, 3 and 5 years, respectively. Risks for cancer death were 19.8%, 36.7% and 41.8% at 1, 3 and 5 years, respectively. In univariate analysis, heavy smoking at diagnosis and the following clinical variables were associated with OS and CSS probabilities (Table 3) : BMI in log-rank P < 0.05 and fever symptoms; ECOG PS; nephrectomy; anemia; serum corrected Ca level; serum LDH value; serum ALP value; serum Crea value; serum CRP value and clinical stage in log-rank P < 0.001.
Extension of the Cox proportional hazards model was used to build the stepwise multivariate model. The initial Cox proportional hazards model using cigarette smoking status at diagnosis and confounding variables (multivariate model 1 in Table 4 ) showed the following variables, including heavy smoking at diagnosis, to be independent predictors of OS: heavy smoking at diagnosis; underweight; fever symptoms; serum LDH value and serum CRP value in P < 0.05; ECOG PS; nephrectomy; serum Crea value and clinical stage in P < 0.001. Results from the second Cox proportional hazards model using heavy smoking at diagnosis and another eight significant variables, which were significant factors in initial model, among 603 cases without missing values showed that all nine variables were independent (multivariate model 2 in Table 4) .
Results of the third Cox proportional hazards model for CSS using these nine variables (multivariate model 3 in Table 4) showed that all nine variables were significantly independent (P < 0.05) for CSS.
For smoking status, 20 cigarettes or more per day was an independent prognostic factor of OS and CSS. Figure 1A and B individually shows OS and CSS curves for cigarette smoking status at diagnosis. OS ( Fig. 2A) and CSS curves (Fig. 2B) for each cigarette smoking status adjusted for the other eight independent factors are also shown.
When stratified according to clinical stage, patients at Stage 3 (logrank, P = 0.0008) showed a greater effect on CSS with cigarette smoking compared with those at Stage 4 (log-rank, P = 0.12 
Discussion
We have shown that excessive smoking continuity is associated with poor survival in advanced RCC, especially in Stage 3. In the current study, smoking more than 20 cigarettes per day was an independent prognostic factor of OS and CSS in advanced RCC. Although the role of cigarette smoking in carcinogenesis is well established, its prognostic value remains controversial in Japanese patients with RCC. Previous Japan collaborative cohort study showed association of smoking with the risk of kidney cancer death. This cohort study showed heavy smokers (Brinkman index > 1200) was suggested to increase the risk of RCC incidence and/or progression (14) . Several studies have reported that a history of smoking is associated with worsening pathological features and survival outcomes (15) (16) (17) , and that the risk for mutated p53 is high (18) . Cigarette smoking is thought to increase the incidence of RCC by increasing the somatic mutation load. Although increases in the numbers of mutations accumulated in normal kidney tissue cells with smoking a pack of cigarettes per day for a year were small (3), the total number of mutations was higher in smokers compared with non-smokers for RCC. This accumulation of genetic mutations is considered to be one reason behind the poor outcomes in advanced RCC. Other mechanisms of worser progression may be involved, such as changes in the immune system (19) and angiogenesis (20) , or tolerance induction of immunotherapy or vascular endothelial growth factor/ tyrosine kinase inhibitor medication (21) . In this study, the effect on prognosis was stronger in patients with Stage 3 at high risk of having potential metastatic cancer cells after nephrectomy. The effect of continuous smoking on prognosis may be influenced in a relatively long clinical course. The impact of continuing smoking on prognosis may have indirect effects such as changes in the immune system and the surrounding environment as well as direct effects on cancer cells. For confounding factors, the following lifestyle prognostic factors in patients with RCC have been reported: age (22) ; obesity (23); cigarette smoking (24, 17) ; higher cumulative cigarette smoking exposure (17) ; alcohol intake (15) and diabetes (25) . It has been paradoxically reported that obesity has a positive effect on survival in metastatic RCC (23) . In the current study, a BMI higher than 25 was a positive prognostic factor of OS and CSS in univariate analysis (P < 0.05), but was not significant in multivariate analysis. Age and diabetes were not significant factors in univariate and multivariate analyses.
The strength of the study was that we could compare the patient situation at diagnosis and the prognosis of renal cell carcinoma at national wide scale. This study had some limitations. First, there are limitations inherent in retrospective epidemiological analysis and our cases were heterogeneous by multi-institutional design. Second, smoking status was based on self-reports with an inherent recall bias. Also, it was not possible to evaluate total cumulative cigarette smoking exposure and a more detailed smoking status. We did not observe the impact of outcomes regarding smoking cessation. Third, we could not analyze the relationship between pathological features and smoking status. We could not investigate all reported confounding factors. Potential interactions with confounding factors such as other lifestyle habits and healthcare medication cannot be excluded. Fourth, the total number of patients who were active heavy smokers is relatively small (n = 87). More, 260 cases (27%) of total cases had missing data of smorking status, and our multivariate analysis was used on only existed data of smoking status. Data-dependent variable selection to develop an initial model using stepwise selection has increased the risk for overfitting the models to our data. It is necessary to verify the results with other Japanese cohorts using multi-institutional collaboration.
In conclusion, our report was a national study evaluating survival data of newly diagnosed RCC in Japan. Despite several limitations, the Japanese database presents an extensive cohort for evaluating the impact of advanced RCC survival and smoking status at diagnosis. Smoking more than 20 cigarettes per day at diagnosis was associated with poorer survival in this population of patients with advanced RCC, especially in Stage 3. Further studies are necessary to understand how cigarette smoking worsens progression and metastasis. Our data and previous studies suggest that active cigarette smoking is an independent risk factor for a poor RCC prognosis. Intervention trial is necessary to guide the final answer as to whether smoking cessation of the patients with advanced RCC improves the prognosis.
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